Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

610 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
AZD9567 versus prednisolone in patients with active rheumatoid arthritis: A phase IIa, randomized, double-blind, efficacy, and safety study.
van Laar JM, Lei A, Safy-Khan M, Almquist J, Belfield G, Edman K, Öberg L, Angermann BR, Dillmann I, Berntsson P, Etal D, Dainty I, Astbury C, Belvisi MG, Nemes S, Platt A, Prothon S, Samuelsson S, Svanberg P, Keen C; SEMRA study group. van Laar JM, et al. Among authors: lei a. Clin Transl Sci. 2023 Dec;16(12):2494-2506. doi: 10.1111/cts.13624. Epub 2023 Oct 23. Clin Transl Sci. 2023. PMID: 37873558 Free PMC article. Clinical Trial.
Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator.
Singh D, Balaguer V, Astbury C, Wählby-Hamrén U, Jimenez E, Seoane B, Villarroel C, Lei A, Aggarwal A, Psallidas I. Singh D, et al. Among authors: lei a. Respir Res. 2020 Sep 9;21(Suppl 1):102. doi: 10.1186/s12931-020-01347-7. Respir Res. 2020. PMID: 32907566 Free PMC article. Clinical Trial.
Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies.
Balaguer V, Albayaty M, Jimenez E, Wählby-Hamrén U, Astbury C, Seoane B, Malice MP, Lei A, Aggarwal A, Psallidas I. Balaguer V, et al. Among authors: lei a. Respir Res. 2020 Sep 9;21(Suppl 1):212. doi: 10.1186/s12931-020-01474-1. Respir Res. 2020. PMID: 32907575 Free PMC article. Clinical Trial.
The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD.
Singh D, Beier J, Astbury C, Belvisi MG, Da Silva CA, Jauhiainen A, Jimenez E, Lei A, Necander S, Smith JA, Wählby Hamrén U, Xin W, Psallidas I. Singh D, et al. Among authors: lei a. Eur Respir J. 2022 Apr 7;59(4):2100972. doi: 10.1183/13993003.00972-2021. Print 2022 Apr. Eur Respir J. 2022. PMID: 34503985 Free PMC article. Clinical Trial.
A Randomized Phase I Study of the Anti-Interleukin-33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease.
Reid F, Singh D, Albayaty M, Moate R, Jimenez E, Sadiq MW, Howe D, Gavala M, Killick H, Williams A, Krishnan S, Godwood A, Shukla A, Hewitt L, Lei A, Kell C, Pandya H, Newcombe P, White N, Scott IC, Cohen ES. Reid F, et al. Among authors: lei a. Clin Pharmacol Ther. 2024 Mar;115(3):565-575. doi: 10.1002/cpt.3147. Epub 2024 Jan 24. Clin Pharmacol Ther. 2024. PMID: 38115209 Clinical Trial.
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability After Subcutaneous Administration of Tozorakimab in Healthy Chinese Participants.
Li Y, Zhang H, Pandya H, Miao L, Reid F, Jimenez E, Sadiq MW, Moate R, Lei A, Zhou XH, Kell C, Ding J, Zhang G, Zhao L, Ge X. Li Y, et al. Among authors: lei a. Clin Pharmacol Drug Dev. 2024 Jun;13(6):665-671. doi: 10.1002/cpdd.1391. Epub 2024 Mar 25. Clin Pharmacol Drug Dev. 2024. PMID: 38523487 Clinical Trial.
A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink.
Rebordosa C, Plana E, Rubino A, Aguado J, Lei A, Daoud S, Saigi-Morgui N, Perez-Gutthann S, Rivero-Ferrer E. Rebordosa C, et al. Among authors: lei a. Int J Chron Obstruct Pulmon Dis. 2021 May 31;16:1461-1475. doi: 10.2147/COPD.S301624. eCollection 2021. Int J Chron Obstruct Pulmon Dis. 2021. PMID: 34103906 Free PMC article.
Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists.
Rebordosa C, Plana E, Rubino A, Aguado J, Martinez D, Lei A, Daoud S, Saigi-Morgui N, Perez-Gutthann S, Rivero-Ferrer E. Rebordosa C, et al. Among authors: lei a. Int J Chron Obstruct Pulmon Dis. 2022 Aug 2;17:1715-1733. doi: 10.2147/COPD.S363997. eCollection 2022. Int J Chron Obstruct Pulmon Dis. 2022. PMID: 35941901 Free PMC article.
610 results